Compare Ascendis Pharma A/S (ASND) vs Southern Copper Corp (SCCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Southern Copper Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Southern Copper Corp trades at $174.85 (market cap $146.70B). The key difference: Southern Copper Corp is far larger — about 8.3× Ascendis Pharma A/S's market cap, and Southern Copper Corp pays a 2.27% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SCCO | |
|---|---|---|
Market Cap | $17.74B | $146.70B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $218.85 |
52-Week Low | $163.32 | $90.54 |
Enterprise Value | $18.11B | $148.75B |
Dividend Yield | — | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SCCO trades at $175.83, up 0.8% on the day, with a neutral technical signal and bearish moving averages. The stock exhibits strong fundamentals, with revenue growing from $10.0B in 2022 to $13.4B in 2025 and net income margin expanding to 34.13%. Recent earnings beats and a $1.00 dividend payment in May 2026 highlight operational strength. However, valuation ratios like a P/E of 29.77 and P/B of 12.45 suggest premium pricing relative to historical norms.
The outlook for SCCO is mixed; robust earnings growth and positive analyst coverage from Zacks (Strong Buy on July 10, 2026) support upside potential, but high valuations and a consensus price target of $151.58 indicate near-term overvaluation risks. Key risks include commodity price volatility and execution challenges in capital expenditures, while institutional sentiment remains cautious with only 10.34% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
